TY - JOUR
T1 - Effectiveness of seasonal influenza vaccine in community-dwelling elderly people
T2 - a meta-analysis of test-negative design case-control studies
AU - Darvishian, Maryam
AU - Bijlsma, Maarten J.
AU - Hak, Eelko
AU - van den Heuvel, Edwin R.
N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.
PY - 2014/12
Y1 - 2014/12
N2 - Background The application of test-negative design case-control studies to assess the effectiveness of influenza vaccine has increased substantially in the past few years. The validity of these studies is predicated on the assumption that confounding bias by risk factors is limited by design. We aimed to assess the effectiveness of influenza vaccine in a high-risk group of elderly people.Methods We searched the Cochrane library, Medline, and Embase up to July 13,2014, for test-negative design casecontrol studies that assessed the effectiveness of seasonal influenza vaccine against laboratory confirmed influenza in community-dwelling people aged 60 years or older. We used generalised linear mixed models, adapted for test-negative design case-control studies, to estimate vaccine effectiveness according to vaccine match and epidemic conditions.Findings 35 test-negative design case-control studies with 53 datasets met inclusion criteria. Seasonal influenza vaccine was not significantly effective during local virus activity, irrespective of vaccine match or mismatch to the circulating viruses. Vaccination was significantly effective against laboratory confirmed influenza during sporadic activity (odds ratio [OR] 0.69, 95% CI 0.48-0.99) only when the vaccine matched. Additionally, vaccination was significantly effective during regional (match: OR 0-42,95% CI 0.30-0.60; mismatch: OR 0.57,95% CI 0.41-0.79) and widespread (match: 0-54,0.46-0.62; mismatch: OR 0.72,95% CI 0.60-0.85) outbreaks.Interpretation Our findings show that in elderly people, irrespective of vaccine match, seasonal influenza vaccination is effective against laboratory confirmed influenza during epidemic seasons. Efforts should be renewed worldwide to further increase uptake of the influenza vaccine in the elderly population.
AB - Background The application of test-negative design case-control studies to assess the effectiveness of influenza vaccine has increased substantially in the past few years. The validity of these studies is predicated on the assumption that confounding bias by risk factors is limited by design. We aimed to assess the effectiveness of influenza vaccine in a high-risk group of elderly people.Methods We searched the Cochrane library, Medline, and Embase up to July 13,2014, for test-negative design casecontrol studies that assessed the effectiveness of seasonal influenza vaccine against laboratory confirmed influenza in community-dwelling people aged 60 years or older. We used generalised linear mixed models, adapted for test-negative design case-control studies, to estimate vaccine effectiveness according to vaccine match and epidemic conditions.Findings 35 test-negative design case-control studies with 53 datasets met inclusion criteria. Seasonal influenza vaccine was not significantly effective during local virus activity, irrespective of vaccine match or mismatch to the circulating viruses. Vaccination was significantly effective against laboratory confirmed influenza during sporadic activity (odds ratio [OR] 0.69, 95% CI 0.48-0.99) only when the vaccine matched. Additionally, vaccination was significantly effective during regional (match: OR 0-42,95% CI 0.30-0.60; mismatch: OR 0.57,95% CI 0.41-0.79) and widespread (match: 0-54,0.46-0.62; mismatch: OR 0.72,95% CI 0.60-0.85) outbreaks.Interpretation Our findings show that in elderly people, irrespective of vaccine match, seasonal influenza vaccination is effective against laboratory confirmed influenza during epidemic seasons. Efforts should be renewed worldwide to further increase uptake of the influenza vaccine in the elderly population.
KW - LABORATORY-CONFIRMED INFLUENZA
KW - SURVEILLANCE NETWORK
KW - PREVENTING INFLUENZA
KW - SPARSE DATA
KW - TRIVALENT
KW - HOSPITALIZATIONS
KW - SPAIN
KW - CANADA
KW - POPULATION
KW - PROTECTION
U2 - 10.1016/S1473-3099(14)70960-0
DO - 10.1016/S1473-3099(14)70960-0
M3 - Article
C2 - 25455990
SN - 1473-3099
VL - 14
SP - 1228
EP - 1239
JO - Lancet Infectious Diseases
JF - Lancet Infectious Diseases
IS - 12
ER -